<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861702</url>
  </required_header>
  <id_info>
    <org_study_id>BTCRC-GI15-067</org_study_id>
    <nct_id>NCT03861702</nct_id>
  </id_info>
  <brief_title>Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Big Ten Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Big Ten Cancer Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, single-arm, open-label, clinical study to investigate the efficacy and
      tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin,
      and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced
      pancreatic carcinoma (LAPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, single-arm, open-label, clinical study to investigate the efficacy and
      tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin,
      and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced
      pancreatic carcinoma (LAPC). Each subject will be screened for eligibility by evaluation
      including medical history, physical examination, performance status, blood tests, computed
      tomographic (CT) scans, and electrocardiogram. Within 28 days of screening, the consented
      subjects will have a central venous access device placed and then start treatment.

      For every 2-week cycle of FOLFOX-nal-IRI, each subject will receive nal-IRI (irinotecan free
      base 50 mg/m2 intravenously over 90 minutes), oxaliplatin (60 mg/m2 intravenously over 2
      hours), leucovorin (400 mg/m2 intravenously over 2 hours), and 5-fluorouracil 2,400 mg/m2
      intravenously over 46 hours).

      Tumor response will be evaluated every 4 cycles of treatment with CT scans using RECIST 1.1
      criteria. If the tumor becomes surgically resectable and the subject is a surgical candidate
      as determined by a multidisciplinary team, the subject will undergo surgery (at which point
      he/she would enter survival follow-up). If the tumor remains unresectable and there is no
      tumor progression, each subject will be treated up to a total of 12 cycles of FOLFOX-nal-IRI.

      Following treatment with 12 cycles of FOLFOX-nal-IRI, if tumor remains unresectable, the
      subjects may receive further treatment (chemotherapy using the same regimen or of the
      treating physician's choice, or chemoradiation therapy) or observation as determined by the
      physician. During the course of treatment, if the subjects develop unacceptable toxicity
      and/or disease progression, the treatment will be discontinued, and the subjects will be
      further managed at the discretion of the treating oncologists.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a phase II, single-arm, open-label, clinical study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Disease Control Rate (DCR) at 24 weeks for nal-IRI in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI), in subjects with locally advanced pancreatic carcinoma (for the subjects whose tumors remain unresectable following 12 cycles of FOLFOX-nal-IRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Objective response rate (ORR) as determined by the proportion of subjects with either complete response or partial response, as defined by RECIST 1.1, at 8 weeks following initiation of FOLFOX-nal-IRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Objective response rate (ORR) as determined by the proportion of subjects with either complete response or partial response, as defined by RECIST 1.1, at 16 weeks following initiation of FOLFOX-nal-IRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Objective response rate (ORR) as determined by the proportion of subjects with either complete response or partial response, as defined by RECIST 1.1, at 24 weeks following initiation of FOLFOX-nal-IRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Disease Rate (SDR) at 8 Weeks</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Stable disease rate (SDR) as determined by the proportion of subjects with no progression of disease as defined by RECIST 1.1, at 8 weeks following initiation of FOLFOX-nal-IRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Disease Rate (SDR) at 16 Weeks</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Stable disease rate (SDR) as determined by the proportion of subjects with no progression of disease as defined by RECIST 1.1, at 16 weeks following initiation of FOLFOX-nal-IRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Disease Rate (SDR) at 24 Weeks</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Stable disease rate (SDR) as determined by the proportion of subjects with no progression of disease as defined by RECIST 1.1, at 24 weeks following initiation of FOLFOX-nal-IRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects able to undergo surgical resection</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of resectability as determined by the proportion of subjects who undergo surgical resection of tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of serum CA19-9 levels</measure>
    <time_frame>Every 4 weeks, up to 6 months</time_frame>
    <description>The serum levels of CA19-9 prior to initiation of chemotherapy and every 2 cycles (every 4 weeks) following initiation of FOLFOX-nal-IRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Progression-free survival (PFS) as determined by the time interval from the date of first dose of study drug to first documented disease progression or death from any cause, whichever occurs first, if evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>18 months</time_frame>
    <description>Overall survival (OS) as defined as the time interval from the date of the first dose of study drug to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Describe safety and tolerability of (FOLFOX-nal-IRI) by reporting Grade 3 and 4 toxicities as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life as measured at baseline and every 4 cycles (every 8 weeks) using the European Organization for Research and Treatment of Cancer Quality-of-Life Core Questionnaire (EORTC-QLQ-C30).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Locally Advanced Pancreatic Carcinoma(LAPC)</condition>
  <arm_group>
    <arm_group_label>FOLFOX + Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 60 mg/m2 Intravenously (IV) over 2 hours Leucovorin400 mg/m2 IV over 2 hours after completion of oxaliplatin nal-Irinotecan (free base) 50 mg/m2 IV over 90 minutes after completion of leucovorin 5-Fluorouracil 2,400 mg/m2 IV over 46 hours via infusion pump at home
All drugs administered on day 1 of each 14 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)</description>
    <arm_group_label>FOLFOX + Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Irinotecan</intervention_name>
    <description>Liposomal Irinotecan</description>
    <arm_group_label>FOLFOX + Irinotecan</arm_group_label>
    <other_name>nal-Irinotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent and HIPAA authorization for release of personal health
             information. NOTE: HIPAA authorization may be included in the informed consent or
             obtained separately.

          -  Age â‰¥ 18 years at the time of consent.

          -  ECOG Performance Status of 0-1 within 28 days prior to registration.

          -  Histological or cytological confirmation of pancreatic carcinoma.

          -  Measurable disease according to RECIST v1.1 within 28 days prior to registration.

          -  Previously untreated pancreatic carcinoma considered as locally advanced unresectable
             according to NCCN guidelines.

          -  Demonstrate adequate organ function as defined in the protocol, All screening labs to
             be obtained within 14 days prior to initiation of study treatment.

          -  Female subjects of childbearing potential must have a negative serum pregnancy test
             within 7 days of study registration and within 72 hours of Cycle 1 Day 1. NOTE: Female
             subjects are considered of child bearing potential unless they are surgically sterile
             (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)
             or they are naturally postmenopausal for at least 12 consecutive months.

          -  Female subjects of childbearing potential and males must be willing to abstain from
             behaviors that could lead to pregnancy (heterosexual activity, sperm donation, in
             vitro fertilization, etc.) or to use 2 forms of effective methods of contraception
             from the time of informed consent until 180 days after treatment discontinuation. The
             two contraception methods can be comprised of two barrier methods, or a barrier method
             plus a hormonal method.

          -  As determined by the enrolling physician or protocol designee, ability of the subject
             to understand and comply with study procedures for the entire length of the study. The
             subject should be able to understand the purpose and risks of the study and provide a
             signed and dated informed consent form.

        Exclusion Criteria:

          -  Known hypersensitivity to irinotecan liposome, other liposomal products, oxaliplatin,
             5-fluorouracil, leucovorin, or any ingredients in those preparations.

          -  Pre-existing peripheral neuropathy (Grade 3 or 4) during screening.

          -  Major surgery within 4 weeks of starting treatment.

          -  Active uncontrolled cardiac arrhythmia or congestive heart failure (class 3 or 4 as
             defined by the New York Heart Association Functional Classification); or history of
             myocardial infarction, unstable angina; or acute coronary syndrome within 6 months
             prior to enrollment.

          -  Known history of human immunodeficiency virus (HIV), or hepatic cirrhosis caused by
             active infection with hepatitis B virus (HBV, as defined by HBsAg positivity or
             positive DNA). Testing is not required for study entry if there is no clinical
             suspicion.

          -  Any medical condition, life-threatening illness, or organ dysfunction, which in the
             investigator's opinion, can compromise the subject's safety or put the study outcomes
             at unnecessary risk.

          -  Uncontrolled active systemic infection.

          -  Concomitant medications that are prohibited in this study and they cannot be switched
             to alternative medications.

          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
             mother is being treated on study).

          -  Known additional malignancy that is active and/or progressive requiring treatment
             within 2 years of screening for this study; exceptions include basal cell or squamous
             cell skin cancer, in situ cervical or bladder cancer, low-grade prostate cancer, or
             other cancer for which the subject has been disease-free for at least five years.
             Additional exceptions could be considered if agreed by sponsor-investigator and site
             investigator assuming the disease is considered extremely unlikely to confound
             evaluation of disease status.

          -  Treatment with any investigational drug within 30 days prior to registration, or
             within a time interval less than at least 5 half-lives of the investigational agent,
             whichever is longer, prior to the first scheduled day of dosing of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

